Eisai (ESAIY) and Biogen (BIIB) announced that humanized anti-soluble aggregated amyloid-beta monoclonal antibody “LEQEMBI” has been approved for once every four weeks intravenous maintenance dosing by the National Medical Products Administration, NMPA, in China.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIIB:
- Freeport-McMoRan, Biogen, Intel, Uranium Energy, CME Trending by Analysts
- Oracle initiated, Ulta Beauty upgraded: Wall Street’s top analyst calls
- Biogen initiated with a Buy at Jefferies
- Biogen’s Growth Potential Driven by Leqembi Sales and Diversified Pipeline
- Biogen, Eisai announces TGA of Australia approved LEQEMBI